Related Experiment Video
Updated: Jul 17, 2026
Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
Published on: November 1, 2017
Vascular targeting of doxorubicin using cationic liposomes
1Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
Abstract:
Tumor vessel has been recognized as an important target for anticancer therapy. Cationic liposomes have been shown to selectively target tumor endothelial cells, thus can potentially be used as a carrier for chemotherapy agents. In this study, cationic liposomes containing 20 mol% cationic lipid dimethyl dioctadecyl ammonium bromide (DDAB) and loaded with doxorubicin (DOX) were prepared and characterized. The cationic liposomal DOX showed 10.8 and 9.1 times greater cytotoxicity than control PEGylated liposomal DOX in KB oral carcinoma and L1210 murine lymphocytic leukemia cells, and 7.7- and 6.8-fold greater cytotoxicity compared to control neutral non-PEGylated liposomal DOX, repectively, in these two cell lines. Although cationic liposomal DOX had higher tumor accumulation at 30 min after intravenous administration compared to control liposomes (p<0.05), DOX uptake of these liposomes at 24h post-injection was similar to that of PEGylated liposomal DOX (p>0.05) and approximately twice the levels of the free drug and non-PEGylated liposomes. In a murine tumor model generated using L1210 cells, increased survival rate was obtained with cationic liposomal DOX treatment compared to free DOX (p<0.01), neutral liposome control (p<0.01), as well as PEGylated liposomes (p<0.05). In conclusion, the cationic liposomal DOX formulation produced superior in vitro cytotoxicity and in vivo antitumor activity, and warrants further investigation.
Insights
Cationic liposomes loaded with doxorubicin (DOX) demonstrate enhanced anticancer efficacy. This novel formulation shows superior in vitro cytotoxicity and in vivo antitumor activity, offering a promising approach for cancer therapy.
Area of Science:
- Nanomedicine
- Drug Delivery Systems
- Oncology
Background:
- Tumor vasculature is a key target for anticancer therapies.
- Cationic liposomes can selectively target tumor endothelial cells.
- Liposomes serve as potential carriers for chemotherapy agents.
Purpose of the Study:
- To prepare and characterize cationic liposomes loaded with doxorubicin (DOX).
- To evaluate the in vitro cytotoxicity and in vivo antitumor activity of cationic liposomal DOX.
Main Methods:
- Preparation of cationic liposomes containing dimethyl dioctadecyl ammonium bromide (DDAB) and doxorubicin (DOX).
- In vitro cytotoxicity assays using KB oral carcinoma and L1210 murine lymphocytic leukemia cells.
- In vivo studies in a murine tumor model (L1210 cells) assessing tumor accumulation and survival rates.
Main Results:
- Cationic liposomal DOX exhibited significantly higher cytotoxicity compared to control PEGylated and non-PEGylated liposomes.
- Enhanced tumor accumulation of cationic liposomal DOX was observed at 30 minutes post-injection.
- Treatment with cationic liposomal DOX significantly increased survival rates in a murine tumor model.
Conclusions:
- The developed cationic liposomal DOX formulation demonstrates superior in vitro and in vivo anticancer performance.
- This formulation holds promise as an effective drug delivery system for cancer treatment.
- Further investigation into this cationic liposomal DOX is warranted.
